TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Buy” from Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned a consensus rating of “Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $12.08.

A number of equities research analysts have issued reports on the company. Oppenheimer assumed coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Roth Mkm assumed coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They set a “buy” rating and a $11.00 price objective for the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Northland Securities assumed coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective for the company. Finally, Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th.

TriSalus Life Sciences Stock Performance

NASDAQ TLSI opened at $4.12 on Wednesday. TriSalus Life Sciences has a one year low of $3.32 and a one year high of $10.42. The stock has a 50-day moving average of $4.29 and a 200 day moving average of $5.68. The company has a market capitalization of $125.62 million, a price-to-earnings ratio of -1.65 and a beta of 0.49.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela purchased 7,520 shares of the stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $5.20 per share, with a total value of $39,104.00. Following the completion of the acquisition, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. The trade was a 2.03 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 32.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Walleye Capital LLC purchased a new position in TriSalus Life Sciences during the third quarter valued at approximately $66,000. Vestcor Inc purchased a new position in TriSalus Life Sciences during the third quarter valued at approximately $108,000. MSD Partners L.P. purchased a new position in TriSalus Life Sciences during the third quarter valued at approximately $184,000. Wolverine Asset Management LLC purchased a new position in TriSalus Life Sciences during the second quarter valued at approximately $240,000. Finally, Geode Capital Management LLC raised its position in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares in the last quarter. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.